Cargando…
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system, which leads, in many cases, to irreversible disability. More than 15 disease-modifying treatments (DMTs) are available for the treatment of MS. Clinical activity or activity at magnetic resonance imaging (MRI) are n...
Autores principales: | Laroni, Alice, Uccelli, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291063/ https://www.ncbi.nlm.nih.gov/pubmed/32414131 http://dx.doi.org/10.3390/jcm9051450 |
Ejemplares similares
-
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016) -
Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020) -
Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015) -
CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023) -
Human Circulating and Tissue-Resident CD56(bright) Natural Killer Cell Populations
por: Melsen, Janine E., et al.
Publicado: (2016)